Therapeutic aptamers: developmental potential as anticancer drugs

키워드

참고문헌 (45)

1. Scott AM, "Antibody therapy of cancer", Nat Rev Cancer, 12, pp.278~287 (2012)
2. Liu JKH, "The history of monoclonal antibody development-Progress, remaining challenges and future innovations", Ann Med Surg, 3, pp.113~116 (2014)
3. Chames P, "Therapeutic antibodies: successes, limitations and hopes for the future", Br J Pharmacol, 157, pp.220~233 (2009)
4. Tabrizi M, "Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease", AAPS J, 12, pp.33~43 (2010)
5. Miller MJ, "Cancer immunotherapy:present status, future perspective, and a new paradigm of peptide immunotherapeutics", Discov Med, 15, pp.166~176 (2013)
6. Jain RK, "Delivering nanomedicine to solid tumors", Nat Rev Clin Oncol, 7, pp.653~664 (2010)
7. Beckman RA, "Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors", Cancer, 109, pp.170~179 (2007)
8. Sung HJ, "Inhibition of human neutrophil activity by an RNA aptamer bound to interleukin-8", Biomaterials, 35, pp.578~589 (2014)
9. Kim YH, "An RNA aptamer that specifically binds pancreatic adenocarcinoma up-regulated factor inhibits migration and growth of pancreatic cancer cells", Cancer Lett, 313, pp.76~83 (2011)
10. Tuerk C, "Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase", Science, 249, pp.505~510 (1990)
11. Keefe AD, "Aptamers as therapeutics", Nat Rev Drug Discov, 9, pp.537~550 (2010)
12. 공훈영, "Nucleic Acid Aptamers: New Methods for Selection, Stabilization,and Application in Biomedical Science", Biomolecules & Therapeutics, 21(6), pp.423~434 (2013), 한국응용약물학회
13. Sun H, "Oligonucleotide aptamers: new tools for targeted cancer therapy", Mol Ther Nucleic Acids, 3, pp.e182~ (2014)
14. Dong Y, "Aptamer and its potential applications for food safety", Crit Rev Food Sci Nutr, 54, pp.1548~1561 (2014)
15. Song KM, "Aptamers and Their Biological Applications", Sensors (Basel), 12, pp.612~631 (2012)
16. Tan W, "Molecular aptamers for drug delivery", Trends Biotechnol, 29, pp.634~640 (2011)
17. Pendergrast PS, "Nucleic acid aptamers for target validation and therapeutic applications", J Biomol Tech, 16, pp.224~234 (2005)
18. Bates PJ, "Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer", Exp Mol Pathol, 86, pp.151~164
19. Tajrishi MM, "Nucleolin : The most abundant multifunctional phosphoprotein of nucleolus", Commun Integr Biol, 4, pp.267~275 (2011)
20. Zhu J, "Progress in aptamer-mediated drug delivery vehicles for cancer targeting and its implications in addressing chemotherapeutic challenges", Theranostics, 4, pp.931~944 (2014)
21. Laber DA, "Update on the first phase I study of AGRO100 in advanced cancer", J Clin Oncol, 23, pp.3064~ (2005)
22. Ni X, "Nucleic acid aptamers: clinical applications and promising new horizons", Curr Med Chem, 18, pp.4206~4214 (2011)
23. Nagasawa T, "Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF", SDF-1, 1996, pp.382, 635~638
24. Sun X, "CXCL12", CXCR4, Cancer Metastasis Rev, pp.2010, 29[DOI]
25. Shum KT, "Nucleic Acid Aptamers as Potential Therapeutic and Diagnostic Agents for Lymphoma", J Cancer Ther, 4, pp.872~890 (2013)
26. Hoellenriegel J, "The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization", Blood, 123, pp.1032~1039 (2014)
27. Liu SC, "Blockade of SDF-1 after irradiation inhibits tumor recurrences of autochthonous brain tumors in rats", Neuro Oncol, 16, pp.21~28 (2014)
28. Zhou J, "Cell-type-specific, Aptamerfunctionalized Agents for Targeted Disease Therapy", Mol Ther Nucleic Acids, 3, pp.e169~ (2014)
29. Bruno JG, "A review of therapeutic aptamer conjugates with emphasis on new approaches", Pharmaceuticals (Basel), 6, pp.340~357 (2013)
30. Farokhzad OC, "Nanoparticle-aptamer bioconjugates:a new approach for targeting prostate cancer cells", Cancer Res, 64, pp.7668~7672 (2004)
31. Farokhzad OC, "Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo", Proc Natl Acad Sci U S A, 103, pp.6315~6320 (2006)
32. Yu C, "Novel aptamer-nanoparticle bioconjugates enhances delivery of anticancer drug to MUC1-positive cancer cells in vitro", PLoS One, 6, pp.e24077~ (2011)
33. McNamara JO, "Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras", Nat Biotechnol, 24, pp.1005~1015 (2006)
34. Leal M, "Antibody-drug conjugates: an emerging modality for the treatment of cancer", Ann N Y Acad Sci, 1321, pp.41~54 (2014)
35. Perez HL, "Antibody-drug conjugates: current status and future directions", Drug Discov Today, 19, pp.869~881 (2014)
36. Shigdar S, "Aptamers as theranostic agents: modifications, serum stability and functionalisation", Sensors (Basel), 13, pp.13624~13637 (2013)
37. Griffin LC, "In vivo anticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits", Blood, 81, pp.3271~3276 (1993)
38. Davydova AS, "Escort aptamers: new tools for the targeted delivery of therapeutics into cells", Acta Naturae, 3, pp.12~29 (2011)
39. Ng EW, "Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease", Nat Rev Drug Discov, 5, pp.123~132 (2006)
40. Lakhin AV, "Aptamers : problems, solutions and prospects", Acta Naturae, 5, pp.34~43 (2013)
41. Healy JM, "Pharmacokinetics and biodistribution of novel aptamer compositions", Pharm Res, 21, pp.2234~2246 (2004)
42. Ruggiero A, "Paradoxical glomerular filtration of carbon nanotubes", Proc Natl Acad Sci U S A, 107, pp.12369~12374 (2010)
43. Burmeister PE, "Direct in vitro selection of a 2'-O-methyl aptamer to VEGF", Chem Biol, 12, pp.25~33 (2005)
44. Shapiro A, "Anti-VEGF state of the union", Retina Today, pp.32~34 (2012)
45. Kaiser PK, "Balancing risk in ophthalmic prescribing: assessing the safety of anti-VEGF therapies and the risks associated with unlicensed medicines", Graefes Arch Clin Exp Ophthalmol, 250, pp.1563~1571 (2012)

관련 논문AI추천